The estimated Net Worth of Glenn R. Mattes is at least $1.48 Million dollars as of 16 May 2022. Mr Mattes owns over 16,000 units of Tff Pharmaceuticals Inc stock worth over $78,120 and over the last 5 years he sold TFFP stock worth over $751,210. In addition, he makes $654,167 as Pres and CEO & Director at Tff Pharmaceuticals Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Mr Mattes TFFP stock SEC Form 4 insiders trading
Mr has made over 8 trades of the Tff Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 16,000 units of TFFP stock worth $76,480 on 16 May 2022.
The largest trade he's ever made was exercising 108,830 units of Tff Pharmaceuticals Inc stock on 10 November 2020 worth over $272,075. On average, Mr trades about 30,783 units every 93 days since 2019. As of 16 May 2022 he still owns at least 36,000 units of Tff Pharmaceuticals Inc stock.
You can see the complete history of Mr Mattes stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Glenn R. Mattes biography
Glenn R. Mattes is the Pres, CEO & Director at Tff Pharmaceuticals Inc.
What is the salary of Mr Mattes?
As the Pres and CEO & Director of Tff Pharmaceuticals Inc, the total compensation of Mr Mattes at Tff Pharmaceuticals Inc is $654,167. There are no executives at Tff Pharmaceuticals Inc getting paid more.
How old is Mr Mattes?
Mr Mattes is 66, he's been the Pres and CEO & Director of Tff Pharmaceuticals Inc since . There are no older and 4 younger executives at Tff Pharmaceuticals Inc.
What's Mr Mattes's mailing address?
Glenn's mailing address filed with the SEC is 1751 RIVER RUN, SUITE 400, , FORT WORTH, TX, 76107.
Insiders trading at Tff Pharmaceuticals Inc
Over the last 5 years, insiders at Tff Pharmaceuticals Inc have traded over $27,239,579 worth of Tff Pharmaceuticals Inc stock and bought 1,894,491 units worth $5,305,961 . The most active insiders traders include Therapeutics, Inc. Lung, Aaron G.L. Fletcher, and Harlan F Weisman. On average, Tff Pharmaceuticals Inc executives and independent directors trade stock every 25 days with the average trade being worth of $174,967. The most recent stock trade was executed by Harlan F Weisman on 15 August 2023, trading 600,000 units of TFFP stock currently worth $150,000.
What does Tff Pharmaceuticals Inc do?
tff pharmaceuticals, inc. is a clinical-stage biopharma company focused on developing and commercializing drug products based on its patented thin film freezing (tff) technology. our patented thin film freezing (tff) platform makes it possible to turn more molecules into inhalable therapies. this novel technology provides high absorption and yield, uniform particle size, gentle process and endless possibilities. tff pharmaceuticals has two lead drug candidates: voriconazole inhalation powder and tac-lac inhalation powder. the company plans to add to this pipeline by collaborating with large pharmaceutical partners. the tff platform is protected by 42 patents issued or pending in the us and internationally.
What does Tff Pharmaceuticals Inc's logo look like?
Complete history of Mr Mattes stock trades at Tff Pharmaceuticals Inc
Tff Pharmaceuticals Inc executives and stock owners
Tff Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Glenn R. Mattes,
Pres, CEO & Director -
Kirk Allen Coleman,
CFO, Treasurer & Sec. -
Christopher Cano,
COO & VP of Bus. Devel. -
Paul F. Manley,
Head of Regulatory Affairs -
Dr. Anthony J. Hickey Ph.D.,
Chief Scientific Officer -
Dr. Dale Christensen,
Director of Clinical Devel. -
Dr. James Brian Windsor Ph.D.,
Chief Science Officer & Director -
Dr. James Brian Windsor,
Chief Science Officer & Director -
Malcolm Fairbairn,
Director -
Zamaneh Mikhak,
Chief Medical Officer -
Robert S Mills,
Director -
Glenn R. Mattes,
President and CEO -
James Brian Windsor,
Chief Science Officer -
Aaron G.L. Fletcher,
Director -
Randy H Thurman,
Director -
Brandi Roberts,
Director -
Stephen Rocamboli,
Director -
Therapeutics, Inc. Lung,
10% owner -
Michael A Patane,
Director -
Catherine Chai Zon Lee,
Director -
Christopher Cano,
Chief Operating Officer -
Harlan F Weisman,
President and CEO -
Kirk Allen Coleman,
Chief Financial Officer -
Capital L P Double Black Di...,
-
Thomas Braxton King,
Director